FEN1 Endonuclease as a Synthetic Lethal Target for Cancer Therapy
FEN1 核酸内切酶作为癌症治疗的合成致死靶点
基本信息
- 批准号:10467002
- 负责人:
- 金额:$ 62.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-15 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAffectAntineoplastic AgentsBRCA1 MutationBRCA1 geneBRCA2 MutationBRCA2 geneBase Excision RepairsBiological AssayBiological ModelsBreast Cancer cell lineBreast Cancer therapyCancer cell lineCell LineCellsChromosomal RearrangementChromosome BreakageChromosomesClustered Regularly Interspaced Short Palindromic RepeatsColorectal CancerDNADNA biosynthesisDNA replication forkDNA sequencingDataDefectDependenceDevelopmentDiploid CellsDouble Strand Break RepairDropoutDrug TargetingEngineeringEpigenetic ProcessEssential GenesEvaluationEvolutionFrequenciesGenesGeneticGenetic studyGenomic DNAGenomic InstabilityGenomicsGerm-Line MutationGoalsGuide RNAHereditary Breast and Ovarian Cancer SyndromeHomologous GeneHumanHuman GenomeHypersensitivityIn VitroInformaticsInheritedKnock-outKnowledgeLaboratoriesLethal GenesLibrariesMaintenance TherapyMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of ovaryMeasuresMetaphaseMiningMusMutateMutationOkazaki fragmentsPARP inhibitionPathway AnalysisPharmacologyProcessProgression-Free SurvivalsRTH-1 NucleaseResearchResistanceScreening ResultSmall Interfering RNASpecificitySuppressor GenesTestingTherapeutic AgentsValidationYeastsbasebrca genecancer cellcancer genomecancer genomicscancer therapycancer typecandidate selectioncandidate validationendonucleasegenome integritygenome-widehomologous recombinationimprovedin silicoin vivoinhibitorknock-downmalignant breast neoplasmmutantnucleasepredictive signaturerational designrecombinational repairreplication stressresistance mechanismresponsesmall moleculetargeted cancer therapytherapeutic developmenttherapeutic targettherapy designtranscriptomicstumor xenograftvalidation studiesyeast geneticsyeast genome
项目摘要
PROJECT SUMMARY
Gross chromosomal rearrangements (GCRs), a type of genome instability, are often seen in inherited and
sporadic cancers and are an important driver of malignant progression. For example, hereditary breast and
ovarian cancers resulting from BRCA1 and BRCA2 germline mutations suffer from homologous recombination
repair (HRR) defects that increase GCRs in model systems. Our previous studies have established a
comprehensive network of genome instability suppressor (GIS) genes in yeast and demonstrated in silico that
human homologs of these yeast GIS genes are genetically and/or epigenetically altered across many cancer
types. From yeast genetic studies, we have also identified and rank-ordered synthetic lethal (SL) partners of
non-essential GIS genes. The feasibility of targeting SL genetic interactions for rational cancer therapy has
been supported by the application of PARP inhibitors for maintenance therapy of breast and ovarian cancers
with BRCA1 or BRCA2 defects. To exploit additional SL interactions for cancer therapy, this proposal aims to
leverage the wealth of knowledge on GIS genes and their SL partners developed in yeast to guide the
development of therapeutics that target human GIS gene defects that cause GCRs in cancer. Specifically, the
proposed studies will focus on the human Flap Endonuclease 1 (FEN1), the homolog of yeast RAD27, which
has the highest number of SL-interactions with GIS genes of a variety of functions. FEN1 processes Okazaki
fragments during lagging strand DNA synthesis and acts in long-patch base excision repair but is itself non-
essential. To develop this nuclease as a target for treating cancers with defects in BRCA1, BRCA2 and other
FEN1-SL partner GIS genes, we propose to carry out the following lines of research: AIM 1) To expand
ongoing CRISPR-dropout screens and validation studies in cell lines and mice to (a) identify human genes in
which defects cause sensitivity to our proprietary FEN1-inhibitors of highly potency and specificity and (b)
define FEN1 SL-partner genes as well as cancer omics signatures that can be targeted with FEN1 inhibitors to
induce SL; AIM 2) To combine informatics and cell-based validation approaches for a deep-dive into cancer
omics and gene essentiality data to identify the spectrum and signatures of cancers amenable to therapeutic
targeting with FEN1 inhibitors; AIM 3) To apply an array of genetics-based approaches to investigate
mechanisms for acquired resistance to FEN1 inhibitors and to compare resistance to FEN1 versus PARP
inhibitors; and, AIM 4) To determine the effects of FEN1 inhibition on DNA replication, fork stability, and
chromosome integrity in BRCA1 and BRCA2 mutant cells to test the hypothesis that FEN1 inhibitors induce
irreparable damage to replication forks in HRR-deficient cancer cells to cause lethality. These mechanistic
studies will be extended to other validated FEN1-SL partner genes. These projects will greatly accelerate the
development of FEN1 inhibitors to target cancer genome instability and will establish an experimental platform
for evaluation and development of other potential therapeutic targets to be identified by the proposed research.
项目总结
总染色体重排(GCRs)是基因组不稳定的一种,常见于遗传性和非遗传性疾病。
散发性癌症是恶性进展的重要驱动力。例如,遗传性乳房和
BRCA1和BRCA2胚系突变导致的卵巢癌发生同源重组
修复(HRR)增加模型系统中GCR的缺陷。我们之前的研究已经建立了一个
酵母基因组不稳定性抑制基因的全面网络和在硅胶中的证明
这些酵母地理信息系统基因的人类同源基因在许多癌症中都发生了遗传和/或表观遗传改变
类型。从酵母遗传研究中,我们还识别并排序了合成致死(SL)合作伙伴
非必要的地理信息系统基因。靶向SL基因交互作用用于合理的癌症治疗的可行性
PARP抑制剂在乳腺癌和卵巢癌维持治疗中的应用
有BRCA1或BRCA2缺陷。为了开发更多的SL相互作用用于癌症治疗,这项提议旨在
利用在酵母中开发的关于GIS基因及其SL合作伙伴的丰富知识来指导
针对导致癌症GCR的人类地理信息系统基因缺陷的治疗方法的发展。具体地说,
拟议的研究将集中在人瓣内切酶1(FEN1),它是酵母RAD27的同源物,它
与具有多种功能的地理信息系统基因具有最高数量的SL-互作。FEN1处理冈崎
在滞后的链DNA合成过程中的片段,并在长补丁碱基切除修复中起作用,但本身不是
必不可少的。开发这种核酸酶作为治疗BRCA1、BRCA2和其他基因缺陷癌症的靶点
针对FEN1-SL伙伴地理信息系统基因,我们建议开展以下几个方面的研究:目的1)拓展
目前正在对细胞系和小鼠进行CRISPR-Dropr筛选和验证研究,以(A)在
哪些缺陷会导致对我们专有的高度有效和特异的FEN1抑制剂的敏感性,以及(B)
定义FEN1 SL伙伴基因以及可被FEN1抑制剂靶向的癌症组学特征
诱导SL;目标2)将信息学和基于细胞的验证方法相结合,深入研究癌症
组学和基因重要性数据,以确定适合治疗的癌症的谱系和特征
以FEN1抑制剂为靶点;目的3)应用一系列基于遗传学的方法来研究
FEN1抑制剂获得性耐药机制及对FEN1与PARP耐药性的比较
抑制剂;以及,目的4)确定抑制FEN1对DNA复制、分叉稳定性和
BRCA1和BRCA2突变细胞的染色体完整性以验证FEN1抑制剂诱导
对HRR缺陷的癌细胞复制造成不可修复的损害,从而导致致命性。这些机械式的
研究将扩展到其他经过验证的FEN1-SL伙伴基因。这些项目将大大加快
开发针对癌症基因组不稳定的FEN1抑制剂并将建立一个实验平台
用于评估和开发拟议研究将确定的其他潜在治疗靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard D Kolodner其他文献
Richard D Kolodner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard D Kolodner', 18)}}的其他基金
FEN1 Endonuclease as a Synthetic Lethal Target for Cancer Therapy
FEN1 核酸内切酶作为癌症治疗的合成致死靶点
- 批准号:
10675534 - 财政年份:2021
- 资助金额:
$ 62.67万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 62.67万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 62.67万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 62.67万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 62.67万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 62.67万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 62.67万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 62.67万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 62.67万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 62.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 62.67万 - 项目类别:
Studentship